Headlines about Oxford Immunotec Global (NASDAQ:OXFD) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.4734884714409 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Oxford Immunotec Global (NASDAQ:OXFD) opened at $12.19 on Monday. Oxford Immunotec Global has a 1-year low of $10.81 and a 1-year high of $19.51. The company has a market cap of $312.73, a PE ratio of -6.03 and a beta of -0.09. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, October 31st. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. Oxford Immunotec Global had a negative net margin of 45.74% and a negative return on equity of 38.42%. equities research analysts forecast that Oxford Immunotec Global will post -2.17 earnings per share for the current fiscal year.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.11% of the stock is currently owned by company insiders.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with our FREE daily email newsletter.